SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending with intense anticipation for its Phase 3 REGAL trial results, as the extended timeline is widely seen by the community as a positive indicator of 'curative outcomes' and a potential buyout. Investors are largely dismissing bearish sentiment and focusing on increasing institutional interest and the transformative potential of the company's dual cancer platforms.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is actively discussed amid conflicting reports on the Middle East conflict; bulls eye a "Trump pump" after claims of the war being "pretty much done," while bears highlight rising oil prices and Iranian denials, fueling concerns of manipulation and a market reversal.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending following multiple analyst upgrades with significantly higher price targets and anticipation around management's comments on stabilizing the BetterHelp segment and addressing debt. The community is actively debating its extreme undervaluation compared to sector peers and its strong free cash flow, fueling speculation of a potential short squeeze amid optimism for its global virtual care platform and AI initiatives.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following a substantial Q4 earnings beat, driven by strong MIPLYFFA sales, which has sparked widespread community optimism about the company's shift to profitability and its undervalued status, with many anticipating further upside from upcoming European approval.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas (ONDS) is actively discussed after announcing a merger with U.S. defense prime contractor Mistral Inc., a move many view as a transformative step providing direct access to significant Department of Defense programs and expanding its role in the autonomous defense market. While bulls are enthusiastic about this strategic positioning, community dialogue also reflects concerns regarding potential share dilution from the all-stock deal and its immediate impact on stock performance ahead of upcoming earnings.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending due to a bullish analyst upgrade and the upcoming R2 vehicle reveal, fueling community debate on its path to profitability and scalability, especially as rising oil prices present both opportunities and challenges for the broader EV sector.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending amidst community discussion surrounding a recent deadline for submitting crucial Full Self-Driving data to NHTSA, which many believe will impact the stock's "autonomy premium" and regulatory outlook. This comes as the company faces a series of executive departures, adding to investor scrutiny of its valuation and market position against intensifying EV competition.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending due to investor concerns over a recently announced convertible senior notes offering, which has sparked questions about potential dilution and management's confidence despite a strong cash position. This comes amidst ongoing community speculation regarding a potential buyout and anticipation for accelerating sales of its gene therapy, Casgevy, and future pipeline updates.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is heavily discussed ahead of its earnings report, with investor sentiment torn between the potential of its AI infrastructure and cloud growth, versus significant concerns over its substantial debt load and capital expenditures, particularly after recent developments around its data center partnerships.

Crane Harbor Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 2, 2025 and is headquartered in Philadelphia, PA.

Crane Harbor Acquisition Corp. - Ordinary Shares - Class A

Crane Harbor Acquisition Corp.

Crane Harbor Acquisition Corp. (CHAC) is generating significant buzz ahead of its anticipated business combination with Xanadu Quantum Technologies, a leading photonic quantum computing firm. The community is focused on Xanadu's innovative room-temperature technology and software platform, driving discussions around potential pre-merger momentum within the speculative quantum sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
